Baseline absolute metabolite concentrations in NAWM, LWM, and GMa
| Natalizumab (n = 25) | IFNb/GA (n = 18) | Controls (n = 12) | ||||||
|---|---|---|---|---|---|---|---|---|
| NAWM | LWM | GM | NAWM | LWM | GM | WM | GM | |
| tCr | ||||||||
| Frontal | 4.86 ± 0.71 | 4.35c ± 0.58 | 8.70 ± 1.89 | 4.93 ± 0.92 | 4.95 ± 0.90 | 8.70 ± 1.41 | 4.93 ± 0.64 | 8.48 ± 1.31 |
| Semiovale | 4.67 ± 0.63 | 4.30c ± 0.81 | 4.83 ± 0.75 | 4.41b ± 0.77 | 4.72 ± 0.60 | |||
| Parietal | 4.52 ± 0.62 | 4.42 ± 0.52 | 7.78 ± 0.88 | 4.72 ± 0.69 | 4.57 ± 0.93 | 8.24 ± 1.02 | 4.58 ± 0.45 | 7.48 ± 0.99 |
| tNAA | ||||||||
| Frontal | 7.17 ± 1.20 | 5.89c ± 0.81 | 11.1 ± 1.74 | 7.06 ± 1.16 | 6.75 ± 1.54 | 10.93 ± 1.61 | 7.62 ± 0.96 | 11.66 ± 1.37 |
| Semiovale | 7.96 ± 0.87 | 6.70c ± 1.51 | 8.25 ± 1.56 | 7.05c ± 1.17 | 8.51 ± 0.94 | |||
| Parietal | 7.43d ± 1.05 | 6.55c ± 0.74 | 10.51 ± 1.08 | 7.59 ± 0.98 | 7.08 ± 1.24 | 11.52 ± 1.46 | 8.22 ± 0.81 | 10.89 ± 1.30 |
| Cho | ||||||||
| Frontal | 1.50 ± 0.20 | 1.51 ± 0.25 | 2.16 ± 0.49 | 1.59 ± 0.28 | 1.64 ± 0.29 | 2.11 ± 0.45 | 1.62 ± 0.25 | 2.08 ± 0.39 |
| Semiovale | 1.44 ± 0.19 | 1.42 ± 0.28 | 1.53 ± 0.21 | 1.49 ± 0.28 | 1.49 ± 0.16 | |||
| Parietal | 1.13 ± 0.24 | 1.36 ± 0.19 | 1.31 ± 0.22 | 1.34 ± 0.23 | 1.39 ± 0.27 | 1.36 ± 0.24 | 1.37 ± 0.17 | 1.13 ± 0.20 |
| mIns | ||||||||
| Frontal | 4.82e ± 1.18 | 5.29 ± 1.01 | 7.49 ± 1.57 | 4.44 ± 0.92 | 5.45c ± 1.51 | 7.30 ± 1.11 | 3.90 ± 0.65 | 7.00 ± 1.16 |
| Semiovale | 4.47e ± 1.18 | 4.76 ± 0.91 | 4.27 ± 0.69 | 4.71 ± 1.01 | 3.56 ± 0.44 | |||
| Parietal | 4.79e ± 0.64 | 5.59b ± 1.07 | 6.47 ± 0.91 | 4.98 ± 0.93 | 5.32 ± 1.42 | 6.47 ± 0.83 | 4.01 ± 0.62 | 5.85 ± 0.52 |
| Glu | ||||||||
| Frontal | 6.34 ± 1.46 | 5.36b ± 1.13 | 12.96 ± 2.98 | 5.86 ± 1.18 | 6.03 ± 1.48 | 12.71 ± 2.57 | 6.25 ± 0.96 | 14.01 ± 2.40 |
| Semiovale | 5.38 ± 1.08 | 4.73b ± 1.16 | 5.50 ± 0.91 | 5.11 ± 0.96 | 5.49 ± 0.72 | |||
| Parietal | 5.17 ± 1.34 | 4.22b ± 0.94 | 12.99 ± 3.87 | 5.37 ± 1.57 | 4.80 ± 0.68 | 12.68 ± 1.44 | 5.31 ± 0.67 | 11.81 ± 1.85 |
↵a In mmol/L tissue, mean ± SD. Absolute metabolite concentrations (mmol/L) of NAWM, GM, WM, and LWM in the frontal, centrum semiovale, and parietal regions averaged over the subjects at the baseline measurement.
↵b Significant difference within the group between NAWM and LWM in the same region of the baseline measurement (P < .05).
↵c Significant difference within the group between NAWM and LWM in the same region of the baseline (P < .01).
↵d Significant differences between patients treated with natalizumab and healthy controls including all the time points (P < .05).
↵e Significant differences between patients treated with natalizumab and healthy controls including all the time points (P < .01).